MA31571B1 - Composes organiques - Google Patents
Composes organiquesInfo
- Publication number
- MA31571B1 MA31571B1 MA32544A MA32544A MA31571B1 MA 31571 B1 MA31571 B1 MA 31571B1 MA 32544 A MA32544 A MA 32544A MA 32544 A MA32544 A MA 32544A MA 31571 B1 MA31571 B1 MA 31571B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- organic compounds
- alk
- meanings
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
Abstract
L'INVENTION PORTE SUR DES COMPOSÉS DE FORMULE (I) SOUS FORME LIBRE, DE SEL OU DE SOLVATE, OÙ R1, R2 ET R5 ONT LES SIGNIFICATIONS TELLES QU'INDIQUÉES DANS LA DESCRIPTION, LESQUELS COMPOSÉS SONT UTILES POUR LE TRAITEMENT DE MALADIES À MÉDIATION PAR LE RÉCEPTEUR ALK-5 ET/OU ALK-4. L'INVENTION PORTE ÉGALEMENT SUR DES COMPOSITIONS PHARMACEUTIQUES QUI CONTIENNENT LES COMPOSÉS ET SUR DES PROCÉDÉS POUR PRÉPARER LES COMPOSÉS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07113214 | 2007-07-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31571B1 true MA31571B1 (fr) | 2010-08-02 |
Family
ID=38694831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32544A MA31571B1 (fr) | 2007-07-26 | 2010-01-22 | Composes organiques |
Country Status (22)
Country | Link |
---|---|
US (1) | US8143253B2 (fr) |
EP (1) | EP2183027B1 (fr) |
JP (1) | JP5090528B2 (fr) |
KR (1) | KR101150581B1 (fr) |
CN (1) | CN101765442B (fr) |
AT (1) | ATE522249T1 (fr) |
AU (1) | AU2008280135B2 (fr) |
BR (1) | BRPI0813625A2 (fr) |
CA (1) | CA2694261A1 (fr) |
CL (1) | CL2008002184A1 (fr) |
CO (1) | CO6290714A2 (fr) |
CR (1) | CR11207A (fr) |
EA (1) | EA201000123A1 (fr) |
EC (1) | ECSP109898A (fr) |
ES (1) | ES2375425T3 (fr) |
MA (1) | MA31571B1 (fr) |
PE (1) | PE20090506A1 (fr) |
SV (1) | SV2010003463A (fr) |
TN (1) | TN2010000040A1 (fr) |
TW (1) | TW200911814A (fr) |
WO (1) | WO2009013335A1 (fr) |
ZA (1) | ZA201000079B (fr) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101297861B1 (ko) * | 2005-08-30 | 2013-08-19 | 스미또모 가가꾸 가부시키가이샤 | 술포닐클로라이드 화합물의 제조 방법 |
EP2444403A1 (fr) * | 2008-04-18 | 2012-04-25 | Shionogi Co., Ltd. | Composé hétérocyclique doté d'une activité inhibitrice sur PI3K |
US8987273B2 (en) * | 2010-07-28 | 2015-03-24 | Bayer Intellectual Property Gmbh | Substituted imidazo[1,2-B]pyridazines |
WO2012088266A2 (fr) * | 2010-12-22 | 2012-06-28 | Incyte Corporation | Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3 |
WO2013004551A1 (fr) * | 2011-07-01 | 2013-01-10 | Bayer Intellectual Property Gmbh | Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1 |
ES2963218T3 (es) | 2011-12-28 | 2024-03-25 | Global Blood Therapeutics Inc | Productos intermedios para obtener compuestos de benzaldehído sustituidos y métodos para su uso en el aumento de la oxigenación tisular |
WO2013102145A1 (fr) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Composés d'aldéhydes hétéroaryles substitués et leurs procédés d'utilisation dans l'accroissement de l'oxygénation tissulaire |
SG11201408238WA (en) | 2012-06-13 | 2015-01-29 | Incyte Corp | Substituted tricyclic compounds as fgfr inhibitors |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
WO2014051698A1 (fr) | 2012-09-28 | 2014-04-03 | Vanderbilt University | Composés hétérocycliques condensés comme inhibiteurs sélectifs de bmp |
MX2015004151A (es) * | 2012-10-05 | 2015-07-06 | Rigel Pharmaceuticals Inc | Inhibidores del factor de diferenciacion de crecimiento-8 (gdf-8). |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
CA2902711C (fr) | 2013-03-15 | 2021-07-06 | Global Blood Therapeutics, Inc. | Derives de pyridinyl-6-methoxy-2-hydroxybenzaldehyde substitues et compositions pharmaceutiques de ceux-ci pour utilisation dans la modulation de l'hemoglobine |
US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US20160083343A1 (en) | 2013-03-15 | 2016-03-24 | Global Blood Therapeutics, Inc | Compounds and uses thereof for the modulation of hemoglobin |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
WO2014145040A1 (fr) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Composés aldéhydes substitués et leurs procédés d'utilisation pour accroître l'oxygénation tissulaire |
CN111454200A (zh) | 2013-03-15 | 2020-07-28 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
RU2550346C2 (ru) * | 2013-09-26 | 2015-05-10 | Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
CA2916564C (fr) | 2014-02-07 | 2023-02-28 | Global Blood Therapeutics, Inc. | Polymorphes cristallins de la base libre de 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
WO2015157093A1 (fr) * | 2014-04-08 | 2015-10-15 | Rigel Pharmaceuticals, Inc. | Composés de pyridine 2,3-disubstitués utilisés comme inhibiteurs de tgf-bêta et procédés d'utilisation |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
SG10201912511WA (en) | 2015-12-04 | 2020-02-27 | Global Blood Therapeutics Inc | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
CN105418615B (zh) * | 2015-12-09 | 2018-02-02 | 北京工业大学 | 苯甲酰胺衍生物及制备和应用 |
TWI663160B (zh) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
CN106478516A (zh) * | 2016-08-31 | 2017-03-08 | 安徽省鸿鑫生物科技有限公司 | 一种5‑氯哒嗪酮的合成方法 |
CN106478517A (zh) * | 2016-08-31 | 2017-03-08 | 安徽省鸿鑫生物科技有限公司 | 一种2‑甲基5‑氯哒嗪酮的合成方法 |
TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
CN107805252A (zh) * | 2017-10-25 | 2018-03-16 | 上海道亦化工科技有限公司 | 一种基于咪唑并哒嗪的有机电致发光化合物及其用途和有机电致发光器件 |
MA51200A (fr) * | 2017-12-02 | 2020-10-07 | Galapagos Nv | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies |
US10745400B2 (en) | 2018-03-14 | 2020-08-18 | Vanderbuilt University | Inhibition of BMP signaling, compounds, compositions and uses thereof |
SG11202010636VA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Solid forms of an fgfr inhibitor and processes for preparing the same |
WO2019213506A1 (fr) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Sels d'un inhibiteur de fgfr |
US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
MX2021007426A (es) | 2018-12-20 | 2021-09-08 | Incyte Corp | Compuestos de imidazopiridazina e imidazopiridina como inhibidores de cinasa-2 de tipo receptor de activina. |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
WO2021007269A1 (fr) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
CR20220169A (es) | 2019-10-14 | 2022-10-27 | Incyte Corp | Heterociclos bicíclicos como inhibidores de fgfr |
WO2021076728A1 (fr) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Fgfr阻害剤としての三環式複素環 |
CA3162010A1 (fr) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derives d'un inhibiteur de fgfr |
CN114981260A (zh) | 2019-12-19 | 2022-08-30 | 斯特拉斯堡大学 | σ-1受体配体及其用途 |
US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11840546B2 (en) * | 2020-06-12 | 2023-12-12 | Incyte Corporation | Imidazopyridazine compounds and uses thereof |
CN116096719A (zh) | 2020-07-15 | 2023-05-09 | 奇斯药制品公司 | 作为alk5抑制剂的哒嗪基氨基衍生物 |
BR112023000592A2 (pt) | 2020-07-15 | 2023-01-31 | Chiesi Farm Spa | Derivados de pirido oxazina amino como inibidores de alk5 |
EP4182322B1 (fr) | 2020-07-15 | 2024-04-24 | Chiesi Farmaceutici S.p.A. | Dérivés de pyrido-oxazine en tant qu'inhibiteurs d'alk5 |
EP4267584A1 (fr) | 2020-12-23 | 2023-11-01 | Chiesi Farmaceutici S.p.A. | Dérivés de pyrido-oxazine utilisés comme inhibiteurs d'alk5 |
CA3220274A1 (fr) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Heterocycles tricycliques en tant qu'inhibiteurs de fgfr |
CN118201915A (zh) | 2021-09-21 | 2024-06-14 | 奇斯药制品公司 | 作为alk5抑制剂的哒嗪基氨基衍生物 |
WO2023208986A1 (fr) | 2022-04-27 | 2023-11-02 | Chiesi Farmaceutici S.P.A. | Dérivés d'imidazole en tant qu'inhibiteurs d'alk5 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1090189C (zh) | 1996-02-07 | 2002-09-04 | 詹森药业有限公司 | 吡唑并嘧啶类化合物 |
WO2000023450A1 (fr) * | 1998-10-21 | 2000-04-27 | Takeda Chemical Industries, Ltd. | Derives fusionnes de pyridazine, procede de preparation correspondant et utilisation de ces derives |
GB0103926D0 (en) * | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
EP1599482A4 (fr) | 2003-02-28 | 2008-10-01 | Teijin Pharma Ltd | Derives de pyrazolo 1,5-a pyrimidine |
NZ548098A (en) * | 2003-12-31 | 2010-05-28 | Schering Plough Ltd | Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives |
WO2006049339A1 (fr) * | 2004-11-08 | 2006-05-11 | Banyu Pharmaceutical Co., Ltd. | Nouveau dérivé polycyclique d’imidazole |
DK1869049T3 (da) | 2005-03-21 | 2009-05-18 | Lilly Co Eli | Imidazopyridazinforbindelser |
US7557103B2 (en) | 2005-04-05 | 2009-07-07 | Eli Lilly And Company | Imidazopyridazine compounds |
US7750000B2 (en) * | 2005-09-02 | 2010-07-06 | Bayer Schering Pharma Ag | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments |
US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
EP2108017A2 (fr) | 2007-01-30 | 2009-10-14 | Biogen Idec MA, Inc. | Composés d'imidazolone utiles comme antagonistes des récepteurs de tgf-beta type i, alk5 et/ou alk4 |
-
2008
- 2008-07-24 PE PE2008001257A patent/PE20090506A1/es not_active Application Discontinuation
- 2008-07-24 JP JP2010517403A patent/JP5090528B2/ja not_active Expired - Fee Related
- 2008-07-24 CN CN200880100481.6A patent/CN101765442B/zh not_active Expired - Fee Related
- 2008-07-24 EP EP08775322A patent/EP2183027B1/fr active Active
- 2008-07-24 KR KR1020107001656A patent/KR101150581B1/ko not_active IP Right Cessation
- 2008-07-24 CA CA2694261A patent/CA2694261A1/fr not_active Abandoned
- 2008-07-24 AT AT08775322T patent/ATE522249T1/de not_active IP Right Cessation
- 2008-07-24 WO PCT/EP2008/059705 patent/WO2009013335A1/fr active Application Filing
- 2008-07-24 BR BRPI0813625-4A2A patent/BRPI0813625A2/pt not_active IP Right Cessation
- 2008-07-24 AU AU2008280135A patent/AU2008280135B2/en not_active Ceased
- 2008-07-24 EA EA201000123A patent/EA201000123A1/ru unknown
- 2008-07-24 ES ES08775322T patent/ES2375425T3/es active Active
- 2008-07-24 US US12/670,188 patent/US8143253B2/en not_active Expired - Fee Related
- 2008-07-25 TW TW097128501A patent/TW200911814A/zh unknown
- 2008-07-25 CL CL2008002184A patent/CL2008002184A1/es unknown
-
2010
- 2010-01-05 ZA ZA201000079A patent/ZA201000079B/xx unknown
- 2010-01-08 CR CR11207A patent/CR11207A/es not_active Application Discontinuation
- 2010-01-22 TN TNP2010000040A patent/TN2010000040A1/fr unknown
- 2010-01-22 MA MA32544A patent/MA31571B1/fr unknown
- 2010-01-25 EC EC2010009898A patent/ECSP109898A/es unknown
- 2010-01-25 CO CO10007036A patent/CO6290714A2/es not_active Application Discontinuation
- 2010-01-26 SV SV2010003463A patent/SV2010003463A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ECSP109898A (es) | 2010-02-26 |
CL2008002184A1 (es) | 2009-05-08 |
US8143253B2 (en) | 2012-03-27 |
CN101765442A (zh) | 2010-06-30 |
ES2375425T3 (es) | 2012-02-29 |
ATE522249T1 (de) | 2011-09-15 |
CO6290714A2 (es) | 2011-06-20 |
TW200911814A (en) | 2009-03-16 |
WO2009013335A1 (fr) | 2009-01-29 |
CN101765442B (zh) | 2014-09-17 |
CA2694261A1 (fr) | 2009-01-29 |
KR101150581B1 (ko) | 2012-06-11 |
EP2183027B1 (fr) | 2011-08-31 |
EP2183027A1 (fr) | 2010-05-12 |
US20100204235A1 (en) | 2010-08-12 |
AU2008280135A1 (en) | 2009-01-29 |
PE20090506A1 (es) | 2009-05-28 |
AU2008280135B2 (en) | 2012-02-23 |
SV2010003463A (es) | 2010-04-13 |
TN2010000040A1 (en) | 2011-09-26 |
JP5090528B2 (ja) | 2012-12-05 |
EA201000123A1 (ru) | 2010-08-30 |
CR11207A (es) | 2010-02-12 |
ZA201000079B (en) | 2010-09-29 |
KR20100034028A (ko) | 2010-03-31 |
BRPI0813625A2 (pt) | 2014-12-23 |
JP2010534633A (ja) | 2010-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31571B1 (fr) | Composes organiques | |
TN2010000167A1 (en) | Organic compounds | |
TN2010000305A1 (en) | Pyrrolopyrimidines and pyrrolopyridines | |
EA201001687A1 (ru) | Производные имидазопиридина в качестве ингибиторов активиноподобной рецепторной киназы ( alk-4 или alk-5 ) | |
MA32536B1 (fr) | Composes organiques | |
TN2009000180A1 (en) | NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF | |
TW200637863A (en) | Organic compounds | |
BR112013033182A2 (pt) | compostos imidazopiridinil-aminopiridina substituída | |
MX2012013274A (es) | Novedosos derivados de la pirimidina. | |
TW200630366A (en) | Organic compounds | |
BRPI0519292A2 (pt) | compostos orgÂnicos | |
MX2009007436A (es) | Derivados espirociclicos de acido tetronico. | |
PH12016502394A1 (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
WO2013040227A3 (fr) | Composés thérapeutiques | |
WO2008104473A3 (fr) | Inhibiteurs de kinase et procédés d'utilisation de ces derniers | |
WO2007068473A3 (fr) | Composés organiques | |
GB0602951D0 (en) | Organic Compounds | |
GB0428416D0 (en) | Organic compounds | |
TW200800993A (en) | Organic compounds | |
MX2018004696A (es) | Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos. | |
BRPI0507283A (pt) | compostos orgánicos | |
CU20100011A7 (es) | Compuestos orgánicos |